Clinical Operations
Clinical Project ManagementStudy Monitoring and Site ManagementTrial Master File and Document ManagementQuality and Vendor Management SystemsStudy DocumentsRegulatory Affairs
Regulatory StrategyRegulatory WritingAgency Communications and SubmissionsDocument Editorial, QC and SubmissionQC, Review and RedactionLegal RepresentationPharmacovigilanceILAP SubmissionsMedical Communications
Publication PlanningStrategic CommunicationsScientific CommunicationsMedical EducationMedical IllustrationGrant Applications and Project PartnershipReCode eager to conduct their first study in patients in a leading London hospital and needed a CRO with experience in the respiratory field and working with academic/NHS sites. The ReCode team recognised Niche as a trusted regulatory and clinical operations partner with the required experience and attributes. Specifically, Niche coordinated and managed our first patient study in the UK. This included:
ReCode Therapeutics is a US-based, clinical-stage genetic medicines company developing therapeutics for genetically defined diseases with no existing treatment options including primary ciliary dyskinesia and cystic fibrosis. ReCode uses superior delivery to power the next wave of messenger (mRNA) and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. ReCode’s technology aims to transcend the limitations of current genetic medicine delivery systems so that people with rare diseases may fully benefit from disease-modifying, corrective therapeutics. ReCode eager to conduct their first study in patients in a leading London hospital and needed a CRO with experience in the respiratory field and working with academic/NHS sites.
ReCode Therapeutics, whose ambitious vision is to develop genetic therapeutics for defined diseases with no existing treatment options including primary ciliary dyskinesia and cystic fibrosis recognised Niche as a trusted regulatory and clinical operations partner. The Niche team enabled ReCode to actualise their treatment approach from their base in California, USA. Niche’s scientific understanding, therapy area experience and regulatory expertise have proved instrumental in this. Close communication, meticulous planning and coordination between ReCode and Niche have been key to delivery of the clinical programme - this included: